Articles by tag: hae

In vivo gene editing: phase 3 of HAE therapy successful

First ever successful phase 3 in vivo gene editing: lonvo-z therapy reduces HAE attacks by 87%. Learn about the breakthrough and discontinuation of prophylaxis.